NATCOPHARM — Natco Pharma Income Statement
0.000.00%
Last trade - 00:00
- IN₹179.00bn
- IN₹169.32bn
- IN₹27.07bn
- 92
- 31
- 98
- 90
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 20,945 | 19,150 | 20,521 | 19,448 | 27,071 |
Cost of Revenue | |||||
Gross Profit | 16,805 | 14,785 | 15,033 | 13,445 | 20,399 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 13,785 | 14,322 | 15,628 | 18,239 | 19,301 |
Operating Profit | 7,160 | 4,828 | 4,893 | 1,209 | 7,770 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 8,247 | 5,687 | 5,796 | 2,022 | 8,619 |
Provision for Income Taxes | |||||
Net Income After Taxes | 6,424 | 4,581 | 4,424 | 1,700 | 7,153 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 6,444 | 4,608 | 4,409 | 1,700 | 7,153 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 6,444 | 4,608 | 4,409 | 1,700 | 7,153 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 34.3 | 24.5 | 22.8 | 7.35 | 38.5 |
Dividends per Share |